| Product NDC: | 10544-275 |
| Proprietary Name: | Naproxen Sodium |
| Non Proprietary Name: | Naproxen Sodium |
| Active Ingredient(s): | 275 mg/1 & nbsp; Naproxen Sodium |
| Administration Route(s): | ORAL |
| Dosage Form(s): | TABLET |
| Coding System: | National Drug Codes(NDC) |
| Product NDC: | 10544-275 |
| Labeler Name: | Blenheim Pharmacal, Inc. |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | ANDA078314 |
| Marketing Category: | ANDA |
| Start Marketing Date: | 20100322 |
| Package NDC: | 10544-275-15 |
| Package Description: | 15 TABLET in 1 BOTTLE (10544-275-15) |
| NDC Code | 10544-275-15 |
| Proprietary Name | Naproxen Sodium |
| Package Description | 15 TABLET in 1 BOTTLE (10544-275-15) |
| Product NDC | 10544-275 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | Naproxen Sodium |
| Dosage Form Name | TABLET |
| Route Name | ORAL |
| Start Marketing Date | 20100322 |
| Marketing Category Name | ANDA |
| Labeler Name | Blenheim Pharmacal, Inc. |
| Substance Name | NAPROXEN SODIUM |
| Strength Number | 275 |
| Strength Unit | mg/1 |
| Pharmaceutical Classes | Cyclooxygenase Inhibitors [MoA],Nonsteroidal Anti-inflammatory Compounds [Chemical/Ingredient],Nonsteroidal Anti-inflammatory Drug [EPC] |